Prof Giuseppe Rosano (St George's University Hospital, London, UK) discusses DAPA-HF.
1. Could you describe DAPA-HF in your own words and what the results tell us?
2. How does this complement existing SGLT2 data?
3. How should DAPA-HF influence clinical practice for use of SGLT2s in both diabetics and non-diabetics patients?
4. With increasing evidence of SGLT2 benefit what further is needed to influence prescribing habits in cardiology?
Filmed on site at ESC 2019 by Radcliffe Cardiology
Videography: Mike Knight & Tom Green
Interviewer: Liam O'Neill